Dimethyl fumarate (DMF), an FDA-approved drug used in the treatment of multiple sclerosis, has been reported to potentiate oncolytic virotherapy through inhibition of NF-κB activity and limitation of type I IFN response21. Here, NFKB1 is linked to multiple sclerosis.